Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02201290

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopenic, Idiopathic Clinical Trial

Official title:
An Extension Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenia Purpura (ITP)

Clinical Trial Summary

This was an open-label Phase III extension study to evaluate the long-term safety of eltrombopag in pediatric patients with chronic ITP who previously participated in study TRA115450. This study allowed dosing of eltrombopag at an individualized dose for each subject based upon platelet count. The starting dose was based on the subject's dose at the end of the TRA115450 study. The maximum dose was 75 mg daily.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02201290
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date June 18, 2013
Completion date July 4, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT01356511 - High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Phase 4
Completed NCT00540423 - Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00372892 - Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) Phase 2
Not yet recruiting NCT03252457 - Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP Phase 3
Completed NCT00151840 - Efficacy and Safety of IVIG-L in ITP Patients Phase 3
Recruiting NCT05438875 - The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9 Phase 3
Completed NCT02281370 - Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects Phase 1
Terminated NCT00547066 - Study of Veltuzumab (hA20) at Different Doses in Patients With ITP Phase 1/Phase 2
Completed NCT00370331 - RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag Phase 3
Completed NCT00828750 - Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00487968 - Eltrombopag Taste Testing in Healthy Adult Volunteers Phase 1
Withdrawn NCT01317966 - Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia N/A
Not yet recruiting NCT03443570 - Rituximab Combining Bortezomib Versus Rituximab in Management of ITP Phase 3
Completed NCT01610180 - Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) Phase 2
Completed NCT00220727 - Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP Phase 2
Completed NCT02334813 - Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Phase 3
Completed NCT02891109 - Regulatory B Cells and Chronic Immune Thrombocytopenia N/A
Completed NCT00706342 - Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) Phase 2
Completed NCT03258866 - The Study of Different Dose Rituximab in the Treatment of ITP Phase 4
Completed NCT01327872 - Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects Phase 1